Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Impaired awareness of hypoglycemia (IAH) and severe hypoglycemic events (SHEs) cause substantial morbidity and mortality in patients with type 1 diabetes (T1D). Current therapies are effective in preventing SHEs in 50–80% of patients with IAH and SHEs, leaving a substantial number of patients at risk. We evaluated the effectiveness and safety of a standardized human pancreatic islet product in subjects in whom IAH and SHEs persisted despite medical treatment. RESEARCH DESIGN AND METHODS: This multicenter, single-arm, phase 3 study of the investigational product purified human pancreatic islets (PHPI) was conducted at eight centers in North America. Forty-eight adults with T1D for >5 years, absent stimulated C-peptide, and documented IAH and SHEs despite expert care were enrolled. Each received immunosuppression and one or more transplants of PHPI, manufactured on-site under good manufacturing practice conditions using a common batch record and standardized lot release criteria and test methods. The primary end point was the achievement of HbA1c <7.0% (53 mmol/mol) at day 365 and freedom from SHEs from day 28 to day 365 after the first transplant. RESULTS: The primary end point was successfully met by 87.5% of subjects at 1 year and by 71% at 2 years. The median HbA1c level was 5.6% (38 mmol/mol) at both 1 and 2 years. Hypoglycemia awareness was restored, with highly significant improvements in Clarke and HYPO scores (P > 0.0001). No study-related deaths or disabilities occurred. Five of the enrollees (10.4%) experienced bleeds requiring transfusions (corresponding to 5 of 75 procedures), and two enrollees (4.1%) had infections attributed to immunosuppression. Glomerular filtration rate decreased significantly on immunosuppression, and donor-specific antibodies developed in two patients. CONCLUSIONS: Transplanted PHPI provided glycemic control, restoration of hypoglycemia awareness, and protection from SHEs in subjects with intractable IAH and SHEs. Safety events occurred related to the infusion procedure and immunosuppression, including bleeding and decreased renal function. Islet transplantation should be considered for patients with T1D and IAH in whom other, less invasive current treatments have been ineffective in preventing SHEs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Islet cell transplantation, which has been shown to reduce hypoglycemia (48) and restore glucose counter-regulation (49), should be considered for people with type 1 diabetes who experience recurrent severe hypoglycemia (50)”
From Hypoglycemia (2018) · cites this paper as [48]
In the citing paper
“For people with type 1 diabetes with level 3 hypoglycemia and hypoglycemia unawareness that persists despite medical treatment, pancreas transplant alone or human islet transplantation may be an option, but these approaches remain experimental (127,128).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [127]
In the citing paper
“Controlled trials 62,63 and followup of recipients 64,65 in major centres showed that high rates of insulin independence can be reached, and long duration of graft function is also seen; however,”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
In the citing paper
“Nevertheless, islet transplantation continues to be offered, with good outcomes, in many centres because of its effectiveness for treating hypoglycaemia and its usefulness in conjunction with kidney transplantation in people unsuitable for SPK.62”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
In the citing paper
“In addition, regulatory hurdles from the US FDA, despite pivotal trials done by the Collaborative Islet Transplant group, 62 have been a major stumbling block for the development of islet transplantation technology in the USA.”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., & Rajotte, R. V. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430401 · Cited by 5,237
Self-citationStandards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
International trial of the Edmonton protocol for islet transplantation
Shapiro, A. M. J., Ricordi, C., Hering, B. J., Auchincloss, H., Lindblad, R., Robertson, R. P., Secchi, A., Brendel, M. D., Berney, T., Brennan, D. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061267 · Cited by 1,942 · cited 2×
“5,000 islet equivalents (IEQ)/kg for the first dose and $4,000 IEQ/kg for subsequent doses (if any), was prepared from a single pancreas (14) and was transplanted by portal vein infusion.”
MethodResultSelf-citationStandards of Medical Care in Diabetes—2008
Dora, J. M., Kramer, C. K., & Canani, L. H. (2008) · Diabetes Care · doi:10.2337/dc08-0109 · Cited by 1,409
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“Severe hypoglycemia is a debilitating, life-threatening complication of T1D (1,2,6,29) that, in some patients, is refractory to medical treatment (7,8,10).”
BackgroundStandards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
(2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 699
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Clarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651 · cited 1×
“Recipient Selection Inclusion criteria included the following: age 18–65 years; T1D for $5 years; absent stimulated C-peptide; IAH and/ or marked glycemic lability (19,20); and a history of SHEs in the prior 12 months despite medical care provided by an endocrinologist or diabetologist, who asserted that the candidate…”
BackgroundSelf-citation
Research works printed but not linked: 1
- Rodbard, 2007, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus, Endocr Pract, 13, 1
Cited by
Items 301–400 of 705
Improving Clinical Islet Transplantation Outcomes
Roep, B. O. (2020) · Diabetes Care · doi:10.2337/dci19-0080 · Cited by 13
Emamaullee, J. A., Pepper, A. R., & Shapiro, A. M. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809880-6.00056-4 · Cited by 13
Self-citationLee, J., Kim, J., Choi, Y., Park, H., Park, H., Wi, H. J., Yoon, S., Shin, J., Park, J. K., Jung, K. C., et al. (2017) · Xenotransplantation · doi:10.1111/xen.12362 · Cited by 13
Senior, P. A., Almehthel, M. S., Miller, A., & Paty, B. W. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.017 · Cited by 13
Self-citationLega, I. C., Yale, J.-F., Chadha, A., Paty, B., Roscoe, R., Snider, M., Steier, J., Bajaj, H. S., Barnes, T., Gilbert, J., et al. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.08.003 · Cited by 12
“Islet cell [119 e 121] and whole pancreas [83,122 e 124] transplantation have both been shown to reduce hypoglycemia and restore glucose counter-regulation, and should be considered for individuals with type 1 diabetes who experience recurrent level 3 hypoglycemia (see “ Diabetes and…”
BackgroundSelf-citationStavas, J., Silva, A. L., Wooldridge, T. D., Aqeel, A., Saad, T. F., Prakash, R., & Bakris, G. L. (2024) · American Journal of Nephrology · doi:10.1159/000537942 · Cited by 12
“For example, multidose therapy has shown improved durability of insulin protection in islet cell therapy for severe hypoglycemia in type 1 diabetes mellitus [25, 26].”
BackgroundAbuarqoub, D. A., Adwan, S., Zaza, R., Wehaibi, S., Aslam, N., Jafar, H. D., Qinna, N. A., & Awidi, A. (2023) · Pharmaceuticals · doi:10.3390/ph16050649 · Cited by 12
“Nonetheless, one of the drawbacks of this strategy is the limited resources of human islet tissues, the shortage in number of donors and their immunological matching [5].”
BackgroundDhandapani, V., & Vermette, P. (2023) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.35292 · Cited by 12
Islets-on-Chip: A Tool for Real-Time Assessment of Islet Function Prior to Transplantation
Raoux, M., Lablanche, S., Jaffredo, M., Pirog, A., Benhamou, P., Lebreton, F., Wojtusciszyn, A., Bosco, D., Berney, T., Renaud, S., et al. (2023) · Transplant International · doi:10.3389/ti.2023.11512 · Cited by 12
“Moreover, islet transplantation has been demonstrated to prevent the progression of chronic diabetes complications [6 – 8].”
BackgroundMethodEspes, D., Lau, J., & Carlsson, P. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0080 · Cited by 12
Sarkis, S., Silencieux, F., Markwick, K. E., Fortin, M., & Hoesli, C. A. (2017) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.7b00404 · Cited by 12
Oxygen-permeable microwell device maintains islet mass and integrity during shipping
Rojas‐Canales, D. M., Waibel, M., Forget, A., Penko, D., Nitschke, J., Harding, F., Delalat, B., Blencowe, A., Loudovaris, T., Grey, S. T., et al. (2018) · Endocrine Connections · doi:10.1530/ec-17-0349 · Cited by 12
“However, the procedure is currently limited to a small group of T1D patients with brittle diabetes or hypoglycemia unawareness (unawareness of critically low blood glucose levels) (12).”
BackgroundNoguchi, H., Miyagi‐Shiohira, C., Nakashima, Y., Ebi, N., Hamada, E., Tamaki, Y., Kuwae, K., Kitamura, S., Kobayashi, N., Saitoh, I., et al. (2018) · Transplantation · doi:10.1097/tp.0000000000002555 · Cited by 12
Generation of a Transgenic Zebrafish Model for Pancreatic Beta Cell Regeneration
Pourghadamyari, H., Rezaei, M. K., Basiri, M., Tahamtani, Y., Asgari, B., Hassani, S., Meshkani, R., Golmohammadi, T., & Baharvand, H. (2019) · Galen Medical Journal · doi:10.31661/gmj.v8i.1056 · Cited by 12
Bachul, P. J., Gołąb, K., Basto, L., Zangan, S. M., Pyda, J. S., Pérez-Gutiérrez, A., Borek, P., Wang, L., TIBUDAN, M. L., Tran, D.-K., et al. (2021) · Cell Transplantation · doi:10.1177/09636897211001774 · Cited by 12
Senior, P. A. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.09.001 · Cited by 12
Self-citationAnti‐thymoglobulin induction improves neonatal porcine xenoislet engraftment and survival
Gao, Q., Davis, R. D., Fitch, Z. W., Mulvihill, M. S., Ezekian, B., Schroder, P. M., Schmitz, R., Song, M., Leopardi, F. V., Ribeiro, M., et al. (2021) · Xenotransplantation · doi:10.1111/xen.12713 · Cited by 12
Shapoval, O., Engstová, H., Jirák, D., Drahokoupil, J., Sulková, K., Berková, Z., Pop‐Georgievski, O., Holendová, B., Ježek, P., & Horák, D. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c04274 · Cited by 12
The heterogeneity of type 1 diabetes: From immunopathology to immune intervention
Infante, M., Alejandro, R., Fabbri, A., & Ricordi, C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824466-1.00001-7 · Cited by 12
Self-citationCell Therapy for Type 1 Diabetes: From Islet Transplantation to Stem Cells
Sordi, V., Monaco, L., & Piemonti, L. (2022) · Hormone Research in Paediatrics · doi:10.1159/000526618 · Cited by 12
Olsen, C., Wang, C., Abadpour, S., Lundanes, E., Hansen, A. S., Skottvoll, F. S., Scholz, H., & Wilson, S. R. (2022) · Journal of Chromatography B · doi:10.1016/j.jchromb.2022.123577 · Cited by 12
Clinical trial data access: Opening doors with TrialShare
Asare, A. L., Carey, V. J., Rotrosen, D., & Nepom, G. T. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.05.034 · Cited by 12
Ultra-marathon 100 km in an islet-transplanted runner
Codella, R., Adamo, M., Maffi, P., Piemonti, L., Secchi, A., & Luzi, L. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0938-x · Cited by 12
Calcium: A Crucial Potentiator for Efficient Enzyme Digestion of the Human Pancreas
Eich, T., Ståhle, M., Gustafsson, B., Horneland, R., Lempinen, M., Lundgren, T., Rafael, E., Tufveson, G., von Zur‐Mühlen, B., Olerud, J., et al. (2018) · Cell Transplantation · doi:10.1177/0963689718779350 · Cited by 12
Self-citationStrategy towards tailored donor tissue-specific pancreatic islet isolation
Miyazaki, Y., Murayama, K., Fathi, I., Imura, T., Yamagata, Y., Watanabe, K., Maeda, H. A., Inagaki, A., Igarashi, Y., Miyagi, S., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216136 · Cited by 12
Uitbeijerse, B. S., Nijhoff, M. F., Sont, J. K., & de Koning, E. J. P. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16135 · Cited by 12
Islet transplantation for T1DM
Ridler, C. E. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.68 · Cited by 12
Peters, A., Olateju, T., Deschênes, J., Shankarnarayan, S. H., Chua, N. S., Shapiro, A. M. J., & Senior, P. A. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14303 · Cited by 12
“Islet transplantation provides excellent glycemic control and robust protection from severe hypoglycemia (15).”
BackgroundSelf-citationHao, L., Khajouei, F., Rodriguez, J., Kim, S., & Lee, E. J. (2024) · Bioengineering · doi:10.3390/bioengineering11020183 · Cited by 11
“This can be integrated with beta-cells differentiated from induced pluripotent stem cells (iPSCs) to create constructs suitable for autologous transplants [30–33].”
BackgroundPomposelli, T., Schuetz, C., Wang, P., & Yamada, K. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.632605 · Cited by 11
Renewable Human Cell Model for Type 1 Diabetes Research: EndoC-βH5/HUVEC Coculture Spheroids
Porter, J. M., Yitayew, M. Y., & Tabrizian, M. (2023) · Journal of Diabetes Research · doi:10.1155/2023/6610007 · Cited by 11
“While a promising treatment option, long-term success of islet transplants could be improved, with recipients who maintain stable blood glycemia dropping from 87.5% to 71% after one year, with signi fi cant decline thereafter [1, 2].”
BackgroundInfluentialMatsumoto, S., & Matsumoto, K. (2024) · Cells · doi:10.3390/cells13100828 · Cited by 11
Autologous and Allogenous Antibodies in Lung and Islet Cell Transplantation
Nayak, D. K., Saravanan, P. B., Bansal, S., Naziruddin, B., & Mohanakumar, T. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00650 · Cited by 11
“All 48 T1D patients experienced severe hypoglycemic episodes and impaired awareness of hypoglycemia pretransplant, and all maintained a regimen of ATG or basiliximab for induction and sirolimus with low-dose tacrolimus for immunosuppressive maintenance (85).”
BackgroundInfluentialZekarias, K., Kumar, A. F., Moheet, A. A., & Seaquist, E. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.08.015 · Cited by 11
Gao, M. H., Giamouridis, D., Lai, N. C., Guo, T., Xia, B., Kim, Y. C., Huu, V. A. N., Skowronska‐Krawczyk, D., Lantier, L., Bhargava, R., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.12.002 · Cited by 11
Alcazar, O., Hernandez, L. F., Nakayasu, E. S., Piehowski, P., Ansong, C. K., Abdulreda, M. H., & Buchwald, P. (2020) · Journal of Proteomics · doi:10.1016/j.jprot.2020.103826 · Cited by 11
Pancreatic islet xenotransplantation
Graham, M. L., & Schuurman, H. (2017) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2017.11.004 · Cited by 11
Tokito, F., Shinohara, M., Maruyama, M., Inamura, K., Nishikawa, M., & Sakai, Y. (2020) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2020.12.009 · Cited by 11
Akram, J., Menezes, P., Idris, N. I., Thomas, J. E., Darwish, R., Tania, A., Butler, A. E., & Moin, A. S. M. (2025) · Cells · doi:10.3390/cells14242014 · Cited by 10
“Further, experimental islet transplantation studies employ diverse approaches, including intrahepatic versus subcutaneous versus omental sites, different islet numbers, varying degrees of purification, and inconsistent cold ischemia times that confound cross-study comparisons [300,301].”
Saudek, F., Hladíková, Z., Hagerf, B. V., Németová, L., Girman, P., Kříž, J., Marada, T., Habart, D., Berková, Z., Leontovyč, I., et al. (2022) · Transplantation Proceedings · doi:10.1016/j.transproceed.2021.11.037 · Cited by 10
Maanaoui, M., Chetboun, M., Top, I., Elsermans, V., Kerr-Conte, J. A., Mapihan, K. L., Defrance, F., Gmyr, V., Hübert, T., Labalette, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16782-3 · Cited by 10
Identifying Promising Immunomodulators for Type 1 Diabetes (T1D) and Islet Transplantation
Ajmal, N., Bogart, M. C., Khan, P., Max-Harry, I. M., Healy, A. M., & Nunemaker, C. S. (2024) · Journal of Diabetes Research · doi:10.1155/jdr/5151171 · Cited by 10
Comparison of Clostripain and Neutral Protease as Supplementary Enzymes for Human Islet Isolation
Brandhorst, H., Johnson, P., Mönch, J., Kurfürst, M., Korsgren, O., & Brandhorst, D. (2018) · Cell Transplantation · doi:10.1177/0963689718811614 · Cited by 10
Self-citationBiovigilance: A global perspective
Medhi, B., Singh, S., Chandel, S., Sarma, P., HariKrishnaReddy, D., Mishra, A., Kumar, S., Thota, P., Murali, K., & Prakash, A. (2019) · Perspectives in Clinical Research · doi:10.4103/picr.picr_89_18 · Cited by 10
Islet Transplantation - The Canadian Perspective.
Shapiro, A. M. J. (2019) · PubMed · doi:10.32113/cellr4_201911_2799 · Cited by 10
Self-citationA machine learning approach to predict pancreatic islet grafts rejection versus tolerance
Ceballos, G. A., Hernandez, L. F., Paredes, D., Betancourt, L. R., & Abdulreda, M. H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241925 · Cited by 10
The Effects of Photobiomodulation Therapy on Porcine Islet Insulin Secretion
Huang, H.-H., Stillman, T. J., Branham, L. A., & Williams, S. (2022) · Photobiomodulation Photomedicine and Laser Surgery · doi:10.1089/photob.2022.0022 · Cited by 10
Nakafusa, Y., Nitta, N., Ishii, K., Shirasu, N., Iwamoto, T., Nemoto, T., Nakamura, M., Goto, M., Iwata, H., Taniguchi, M., et al. (2022) · Diabetes · doi:10.2337/db21-0684 · Cited by 10
Long, G., Zhang, G., Zhang, F., Li, M., Ye, D., Yang, D., & Yang, Y. (2017) · BioMed Research International · doi:10.1155/2017/4107943 · Cited by 10
Islet vs pancreas transplantation in nonuremic patients with type 1 diabetes
Zarinsefat, A., & Stock, P. G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00034-4 · Cited by 10
Self-citationA Smartphone-Fluidic Digital Imaging Analysis System for Pancreatic Islet Mass Quantification
Yu, X., Zhang, P., He, Y., Lin, E., Ai, H., Ramasubramanian, M. K., Wang, Y., Xing, Y., & Oberholzer, J. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.692686 · Cited by 10
Self-citationCharting the next century of insulin replacement with cell and gene therapies
Lau, H. H., Gan, S. U., Lickert, H., Shapiro, A. M. J., Lee, K., & Teo, A. K. K. (2021) · Med · doi:10.1016/j.medj.2021.09.001 · Cited by 10
Self-citationUtility of Islet Cell Preparations From Donor Pancreases After Euthanasia
Paep, D. L. D., Hulle, F. O. V., Ling, Z., Vanhoeij, M., Hilbrands, R., Distelmans, W., Gillard, P., Keymeulen, B., PIPELEERS, D. G., & Jacobs‐Tulleneers‐Thevissen, D. (2022) · Cell Transplantation · doi:10.1177/09636897221096160 · Cited by 10
Marinac, M., Rickels, M. R., Gaglia, J. L., O’Connell, P. J., Johnson, P., Piemonti, L., Schneider, B., Greenstein, J. L., Dutta, S., & Latres, E. (2025) · Diabetes · doi:10.2337/dbi24-0037 · Cited by 9
Self-citationEvans‐Molina, C., Dor, Y., Lernmark, Å., Mathieu, C., Millman, J. R., Mirmira, R. G., Pociot, F., REDONDO, M. J., Rich, S. S., Richardson, S. J., et al. (2025) · Diabetes · doi:10.2337/dbi25-0011 · Cited by 9
Self-citationBarinova, A. A., Bogomolova, A. Y., Bogomazova, A. N., Borisova, A. A., Киселев, С. Л., & Panova, A. V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178749 · Cited by 9
“Reported adverse outcomes—including transplant rejection, development of basal or squamous cell skin carcinomas, and fatal cases—occur in ≤ 3% of recipients [7,8].”
Role of Cell-Based Therapies in T2D
Ashe, S., & Hebrok, M. (2023) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2023.151432 · Cited by 9
Hypoglycemia in Type 1 Diabetes Mellitus
Şakar, K., & Çınar, N. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004108 · Cited by 9
Burke, J. A., Zhu, Y., Zhang, X., Rios, P., Joshi, I., Lopez, D., Nasir, H., Roberts, S., Rodriguez, Q., McGarrigle, J. J., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk3081 · Cited by 9
“Approximately, 50 to 80% of the islets are destroyed via isolation and infusion ( 9 – 11 ).”
BackgroundSelf-citationFlatt, A. J., MATUS, A. M., Gallop, R., Markmann, E., DALTON-BAKES, C. V., Peleckis, A. J., Liu, C., Naji, A., & Rickels, M. R. (2024) · Diabetes · doi:10.2337/db24-0729 · Cited by 9
Self-citationState of the Art of Bioengineering Approaches in Beta-Cell Replacement
Miller, J., Perrier, Q., Rengaraj, A., Bowlby, J. J., Byers, L. N., Peveri, E., Jeong, W., Ritchey, T., Gambelli, A. M., Rossi, A., et al. (2025) · Current Transplantation Reports · doi:10.1007/s40472-025-00470-y · Cited by 9
“Despite persistent islet graft failure, improved metabolic control and hypoglycemia offer promise in the potentiality of using islet transplantation methods [7].”
Brandhorst, H., Brandhorst, D., Abraham, A., Acreman, S., Schive, S. W., Scholz, H., & Johnson, P. (2020) · Cell Transplantation · doi:10.1177/0963689720952332 · Cited by 9
Parsons, R. F., Baquerizo, A., Kirchner, V. A., Malek, S. K., Desai, C. S., Schenk, A. D., Finger, E. B., Brennan, T. V., Parekh, K. R., MacConmara, M. P., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16740 · Cited by 9
DAMP-modulating nanoparticle for successful pancreatic islet and stem cell transplantation
Jang, S., Jin, S., Kim, H. S., Jeong, Y. Y., Lee, S. J., Hahn, S., Lee, H., Lee, H. S., Kim, J. H., & Lee, D. Y. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121679 · Cited by 9
Long-term effects of islet transplantation
Holmes-Walker, D. J., & Kay, T. W. H. (2016) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000355 · Cited by 9
Madrigal, J. M., Monson, R. S., Hatipoğlu, B., Oberholzer, J., Kondos, G. T., Varady, K. A., & Danielson, K. K. (2017) · Clinical Transplantation · doi:10.1111/ctr.13059 · Cited by 9
Self-citationGearing Up for Stem Cell-derived Beta Cells—Are We Ready?
Shapiro, A. M. J. (2018) · Transplantation · doi:10.1097/tp.0000000000002214 · Cited by 9
Self-citationVeroux, M., Bottino, R., Santini, R., Bertera, S., Corona, D., Zerbo, D., Volti, G. L., Ekser, B., Puzzo, L., Raffaele, M., et al. (2019) · BMC Surgery · doi:10.1186/s12893-018-0452-x · Cited by 9
Cutting-edge Biotechnological Advancement in Islet Delivery Using Pancreatic and Cellular Approaches
Elnashar, M. M. M., Vaccarezza, M., & Al‐Salami, H. (2020) · Future Science OA · doi:10.2144/fsoa-2020-0105 · Cited by 9
Pancreas transplant versus islet transplant versus insulin pump therapy: in which patients and when?
Tamburrini, R., & Odorico, J. S. (2021) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000857 · Cited by 9
“demonstrated that almost 90% of the individuals enrolled saw the elimination of severe hypoglycemic episodes and a reduction of glycated hemoglobin [58].”
BackgroundHigh Concentrations of Etanercept Reduce Human Islet Function and Integrity
Brandhorst, D., Brandhorst, H., Acreman, S., Abraham, A., & Johnson, P. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s294663 · Cited by 9
“Introduction Clinical islet allotransplantation is now established as a successful and safe treatment for reversing life-threatening hypoglycaemia unawareness and restoring euglycemia in prone patients with unstable type 1 diabetes mellitus.(1) Indeed, the outcome of islet allotransplantation alone (ITA) for selected…”
BackgroundAitken, T. J., Crabtree, J. E., Jensen, D. M., Hess, K. H., Leininger, B., & Tessem, J. S. (2021) · Biology of the Cell · doi:10.1111/boc.202100035 · Cited by 9
“This is evidenced by patients that undergo islet replacement therapy have reported insulin independence and successful control of hypoglycemic episodes 5 years posttransplantation (Hering et al., 2016).”
BackgroundBallou, C., Barton, F. B., Payne, E. H., Berney, T., Villard, J., Meier, R. P. H., Baidal, D. A., Alejandro, R., Robien, M. A., Eggerman, T. L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1110544 · Cited by 9
Self-citationChen, C., Peng, S.-J., Wu, P.-Y., Chien, H., Lee, C., Chung, M., & Tang, S. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00605.2020 · Cited by 9
Finishing the odyssey to a stem cell cure for type 1 diabetes
Hunault, L., & Hesselson, D. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00014-5 · Cited by 8
“Indeed, transplant of cadaveric islets into immunosuppressed T1D recipients has shown that excellent glucose control can be achieved 6 , while simultaneously reducing hypoglycemic risk 7 .”
Emerging Diabetes Therapies: Regenerating Pancreatic β Cells
Zhang, H., Wei, Y., Wang, Y., Liang, J., Hou, Y., Nie, X., & Hou, J. (2024) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2024.0041 · Cited by 8
“55 Similarly, a phase 3 clinical trial conducted on 24 T1DM patients after kidney transplantation achieved improvements in hypoglycemia awareness and glucose variability without impairment in kidney allograft function, supporting the safety and effectiveness of the procedure in the postrenal…”
Doppenberg, J. B., van Rooden, R. M., van Dijk, M. C., de Goeij, F. H. C., van der Heijden, F. J., Alwayn, I. P. J., de Koning, E. J. P., de Jonge, J., Engelse, M. A., & Huurman, V. A. L. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.09.034 · Cited by 8
CCL22-expressing Stem Cell–derived Islet Grafts Recruit Regulatory T Cells in Mice
Filatov, E., Sasaki, S., Haque, M., Kar, S., Fung, V. C. W., Mojibian, M., Krentz, N. A. J., MacDonald, K. N., Salim, K., Soukhatcheva, G., et al. (2025) · Transplantation · doi:10.1097/tp.0000000000005463 · Cited by 8
“55,56 The immediate success and long-term functionality of transplanted islets is challenged by many factors such as poor re-vascularization, inflammation, hyperglycemia, allo-and autoimmunity, and toxicity from immunosupression.”
Campbell, S. A., Hubert, M., Johnson, J., Salamon, N., & Light, P. E. (2019) · OBM Transplantation · doi:10.21926/obm.transplant.1902069 · Cited by 8
Grafting Islets to a Dissected Peritoneal Pouch to Improve Transplant Survival and Function
Kumano, K., Vasu, S., Liu, Y., Lo, S., Mulgaonkar, A., Pennington, J., Darden, C. M., Sun, X., Lawrence, M. C., & Naziruddin, B. (2020) · Transplantation · doi:10.1097/tp.0000000000003355 · Cited by 8
“As such, the procedure imposes a risk of portal venous embolic occlusion, hemorrhage, and thrombosis.(5-8) Islet infusions are halted when portal venous pressure exceeds a threshold, and the remaining donor islets are discarded or transplanted to the peritoneal cavity to avoid further risk.”
BackgroundInsulinoma-derived pseudo-islets for diabetes research
Hart, N. J., Weber, C. S., Price, N. D., Banuelos, A., Schultz, M., Huey, B., Harnois, E. R., Gibson, C., Steyn, L. V., Papas, K. K., et al. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00466.2020 · Cited by 8
Turan, A., Zhang, L., Tarique, M., Ulker, V., Arguc, F. N., Badal, D., Yolcu, E. S., & Shirwan, H. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2023.02.021 · Cited by 8
Wu, Y., Zhang, Z., Wu, S., Chen, Z., & Pu, Y. (2023) · Scientific Reports · doi:10.1038/s41598-023-43798-0 · Cited by 8
Pancreatic islets in bed with microvasculature—companions for life
Hoesli, C. A., & Kieffer, T. J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100454 · Cited by 8
Recent research trend in cell and drug delivery system for type 1 diabetes treatment
Im, G., & Bhang, S. H. (2018) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0380-2 · Cited by 8
Advances in Islet Transplantation and the Future of Stem Cell–Derived Islets to Treat Diabetes
Kieffer, T. J., Hoesli, C. A., & Shapiro, A. M. J. (2025) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041624 · Cited by 7
Self-citationSmartphone-microfluidic fluorescence imaging system for studying islet physiology
Yu, X., Xing, Y., Zhang, Y., Zhang, P., He, Y., Ghamsari, F., Ramasubramanian, M. K., Wang, Y., Ai, H., & Oberholzer, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1039912 · Cited by 7
“Human islet transplant is a promising cell-based therapy for Type I diabetes (2), in which isolated islet mass and function are key factors influencing islet transplant outcomes (3, 4).”
BackgroundSelf-citationUrine-derived stem cell therapy for diabetes mellitus and its complications: progress and challenges
Zou, Y., Li, S., Chen, W., & Xu, J. (2023) · Endocrine · doi:10.1007/s12020-023-03552-y · Cited by 7
Chemical Strategies for Improving Islet Transplant Outcomes
Quintana, J. M., Stinchcomb, A. L., Kostyo, J. H., Robichaud, B., Plunk, M. A., & Kane, R. R. (2018) · OBM Transplantation · doi:10.21926/obm.transplant.1804036 · Cited by 7
Pancreatic ductal cells may have a negative effect on human islet transplantation
Marín‐Cañas, S., Estil·les, E., Lladó, L., José, P. S., Nacher, M., Téllez, N., & Montanya, E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220064 · Cited by 7
Holdcraft, R. W., Graham, M. L., Bemrose, M. A., Mutch, L. A., Martis, P. C., Janecek, J. L., Hall, R. D., Smith, B. H., & Gazda, L. S. (2022) · Xenotransplantation · doi:10.1111/xen.12747 · Cited by 7
Omori, K., Qi, M., Salgado, M., Gonzalez, N., Hui, L. T., Chen, K.-T., Rawson, J., MIAO, L. N., Komatsu, H., Isenberg, J. S., et al. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2023.10.001 · Cited by 7
Bozorgi, A., Khazaei, M. R., Bozorgi, M., & Khazaei, M. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4038 · Cited by 7
“3 4 – 6 Autologous cell therapy using stem ‐ and organ ‐ specific cells has gained much attention in treating T1D.”
BackgroundWhite Adipose Tissue as a Site for Islet Transplantation
Sakata, N., Yoshimatsu, G., & Kodama, S. (2020) · Transplantology · doi:10.3390/transplantology1010006 · Cited by 7
“0% and prevention of severe hypoglycemic events at 1 and 2 years after the first ITx, respectively [4].”
BackgroundFeasibility of large experimental animal models in testing novel therapeutic strategies for diabetes
Nagaya, M., Hasegawa, K., Uchikura, A., Nakano, K., Watanabe, M., Umeyama, K., Matsunari, H., Osafune, K., Kobayashi, E., Nakauchi, H., et al. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i4.306 · Cited by 7
Kim, J. M., Hong, S., Shin, J., Min, B., Kim, H. J., Chung, H., Kim, J., Bang, Y. J., Seo, S., Hwang, E., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16704 · Cited by 7
TFNR2 in Ischemia-Reperfusion Injury, Rejection, and Tolerance in Transplantation
Kouyoumdjian, A., Tchervenkov, J., & Paraskevas, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903913 · Cited by 7
Verhoeff, K. K., Marfil‐Garza, B. A., Dajani, K. Z., Bigam, D. L., Anderson, B. L., Kin, T., Lam, A. P., O’Gorman, D., Senior, P. A., & Shapiro, A. M. J. (2023) · Transplantation · doi:10.1097/tp.0000000000004328 · Cited by 7
Self-citationSpontaneous Hypoglycemia After Islet Transplantation: The Case For Using Non-Hepatic Sites
Robertson, R. P. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2850 · Cited by 7
Gerber, P. A., Hochuli, M., Benediktsdóttir, B. D., Zuellig, R. A., Tschopp, O., Glenck, M., de Rougemont, O., Oberkofler, C. E., Spinas, G. A., & Lehmann, R. (2017) · Clinical Transplantation · doi:10.1111/ctr.13153 · Cited by 7
Metadata
- Authors
- Hering, B. J., Clarke, W. R., Bridges, N. D., Eggerman, T. L., Alejandro, R., Bellin, M. D., Chaloner, K., Czarniecki, C. W., Goldstein, J. S., Hunsicker, L. G., Kaufman, D. B., Korsgren, O., Larsen, C. P., Luo, X., Markmann, J. F., Naji, A., Oberholzer, J., Posselt, A. M., Rickels, M. R., Ricordi, C., Robien, M. A., Senior, P. A., Shapiro, A. M. J., Stock, P. G., Turgeon, N. A., & for the Clinical Islet Transplantation Consortium
- Affiliations
- University of Minnesota (US)
- University of Iowa (US)
- National Institutes of Health (US)
- University of Miami (US)
- University of Wisconsin–Madison (US)
- Uppsala University (SE)
- Emory University (US)
- Northwestern University (US)
- Harvard University (US)
- University of Pennsylvania (US)
- Division of Transplantation, University of Illinois Hospital and Health Sciences System, Chicago, IL
- University of California, San Francisco (US)
- University of Alberta (CA)
- Corresponding author
- Clarke, William R.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-04-18
- Volume
- 39
- Issue
- 7
- Pages
- 1230-1240
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC5317236
- OpenAlex
- W2341414956
- Cited by
- 645
- References
- 40
- Citations by year
- 2026: 25 · 2025: 51 · 2024: 47 · 2023: 67 · 2022: 75 · 2021: 88 · 2020: 60 · 2019: 79 · 2018: 73 · 2017: 60 · 2016: 20
- FWCI
- 85.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases
- National Institute for Diabetes and Digestive and Kidney Diseases (U01-AI-089317, 1-AI-089316, 1-AI-065191, U01-DK-085531, 5U01-DK-070431-10, U01-DK-070431, U01-DK-070460, U01-AI-065193, U01-DK-070430, U01-AI-065192)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- type 1 diabetes, islet transplantation, severe hypoglycemia, hypoglycemia unawareness, glycemic control, HbA1c, immunosuppression, bleeding complications, glomerular filtration rate, donor-specific antibodies, renal function decline, islet autoimmunity
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Immunosuppression Therapy, Male, Middle Aged, North America, Islets of Langerhans Transplantation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.